It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
IV iron isomaltoside showed no clear difference in number of responders ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).